Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Schizophr Bull. 2012 Jun;38(4):845-53. doi: 10.1093/schbul/sbq172. Epub 2011 Feb 9.
Scant information exists to guide pharmacological treatment of early-onset schizophrenia. We examine variation across commonly prescribed second-generation antipsychotic medications in medication discontinuation and psychiatric hospital admission among children and adolescents clinically diagnosed with schizophrenia. A 45-state Medicaid claims file (2001-2005) was analyzed focusing on outpatients, aged 6-17 years, diagnosed with schizophrenia or a related disorder prior to starting a new episode of antipsychotic monotherapy with risperidone (n = 805), olanzapine (n = 382), quetiapine (n = 260), aripiprazole (n = 173), or ziprasidone (n = 125). Cox proportional hazard regressions estimated adjusted hazard ratios of 180-day antipsychotic medication discontinuation and 180-day psychiatric hospitalization for patients treated with each medication. During the first 180 days following antipsychotic initiation, most youth treated with quetiapine (70.7%), ziprasidone (73.3%), olanzapine (73.7%), risperidone (74.7%), and aripirazole (76.5%) discontinued their medication (χ(2) = 1.69, df = 4, P = .79). Compared with risperidone, the adjusted hazards of antipsychotic discontinuation did not significantly differ for any of the 4-comparator medications. The percentages of youth receiving inpatient psychiatric treatment while receiving their initial antipsychotic medication ranged from 7.19% (aripiprazole) to 9.89% (quetiapine) (χ(2) = 0.79, df = 4, P = .94). As compared with risperidone, the adjusted hazard ratio of psychiatric hospital admission was 0.96 (95% CI: 0.57-1.61) for olanzapine, 1.03 (95% CI: 0.59-1.81) for quetiapine, 0.85 (95% CI: 0.43-1.70) for aripiprazole, and 1.22 (95% CI: 0.60-2.51) for ziprasidone. The results suggest that rapid antipsychotic medication discontinuation and psychiatric hospital admission are common in the community treatment of early-onset schizophrenia. No significant differences were detected in risk of either adverse outcome across 5 commonly prescribed second-generation antipsychotic medications.
关于早期发病精神分裂症的药物治疗,目前仅有少量信息可供参考。本研究旨在探讨在接受利培酮(n = 805)、奥氮平(n = 382)、喹硫平(n = 260)、阿立哌唑(n = 173)或齐拉西酮(n = 125)单一疗法治疗的儿童和青少年精神分裂症患者中,常见的第二代抗精神病药物在停药和精神病住院方面的差异。研究人员分析了 45 个州的医疗补助索赔文件(2001-2005 年),主要为门诊患者,年龄在 6-17 岁,在开始新的抗精神病药物单一疗法之前被诊断为精神分裂症或相关障碍。采用 Cox 比例风险回归模型,估算了每位患者在 180 天内停药和住院的调整后风险比。在开始使用抗精神病药物后的 180 天内,大多数接受喹硫平(70.7%)、齐拉西酮(73.3%)、奥氮平(73.7%)、利培酮(74.7%)和阿立哌唑(76.5%)治疗的青少年停止了药物治疗(χ²=1.69,df=4,P=0.79)。与利培酮相比,其他 4 种比较药物的抗精神病药物停药的调整后风险比无显著差异。在接受初始抗精神病药物治疗的同时,接受住院精神治疗的青少年比例为 7.19%(阿立哌唑)至 9.89%(喹硫平)(χ²=0.79,df=4,P=0.94)。与利培酮相比,奥氮平(95%CI:0.57-1.61)、喹硫平(95%CI:0.59-1.81)、阿立哌唑(95%CI:0.43-1.70)和齐拉西酮(95%CI:0.60-2.51)的入院调整后风险比分别为 0.96、1.03、0.85 和 1.22。研究结果表明,在社区治疗早期发病精神分裂症时,快速停药和住院治疗很常见。在这 5 种常用的第二代抗精神病药物中,没有发现任何一种不良结局的风险存在显著差异。